Citations 1
BR or R-CHOP induction followed by rituximab maintenance in transplant-ineligible patients with mantle cell lymphoma
Gutmair, Katja , Cunningham, Nicholas , Silkenstedt, Elisabeth , Ramsower, Colleen , Scott, David W. , Dreyling, Martin , Villa, Diego , Scott, David W , Hoster, Eva , Cunningham, Nicholas, Rimsza, Lisa M. , Gerrie, Alina S. , Kluin‐Nelemans, Hanneke C.
No container title available | February 28, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available
Abstract There are no studies directly comparing the efficacy of bendamustine with rituximab (BR) as induction therapy followed by maintenance rituximab (Rm) against rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) followed by Rm in previously untreated, older, transplant-ineligible patients with mantle cell lymphoma (MCL). The objective of this international study was to retrospectively compare the efficacy of these two treatment regimens by pooling and comparing a clinical trial cohort with a population-based cohort. 140 patients treated with R-CHOP and 112 patients treated with BR were evaluable for the analysis of the primary endpoint progression-free survival (PFS). Patients receiving R-CHOP had a more favorable risk profile. Median PFS for the R-CHOP group was 3.93 years (95% CI: 2.79–5.30) and for the BR group 2.88 years (95% CI: 1.84–4.61, p-value = 0.12). The Hazard ratio of PFS of R-CHOP vs. BR adjusted for MIPI score was 0.80 (95% CI: 0.57–1.13, p-value = 0.2) and adjusted for MIPI score, Ki67 and cytology was 0.85 (95% CI: 0.51–1.40, p-value = 0.52). These data indicate that there was no difference regarding the efficacy between R-CHOP + Rm and BR + Rm for previously untreated, older patients with MCL.